摘要：酪氨酸蛋白激酶(PTK)广泛存在于细胞的各种生理过程中，是主要与细胞的生长增殖和分化有关的信号途径。因此，PTK抑制剂具有广泛的多样的生物效应，本文回顾了近年来对PTK抑制剂的研究进展：新型PTK抑制剂的结构活性关系；PTK抑制剂对肿瘤细胞和正常细胞的影响。参考文献：

［1］Jin Najia, Rafat A, Denis E, et al. Communication between tyrosine kinase pathway and myosin light chain kinase pathway in smooth muscle. American Physiology, 1996, 271(4 part 2): H1348

［2］柴希运，秦慧，陈惠黎．蛋白激酶与细胞分化——两种分化诱导剂对酪氨酸蛋白激酶的抑制．生物化学杂志，1993,9: 162

［3］Sharpe T R, Vasios G W. PTK inhibitors for treating osteoarthritis. PCT Int Appl WO 97, 1997, Apr: 11692,3

［4］Traxler P M, Marc L. PTK inhibitors in cancer treatment. Expert Opin Ther Pat, 1997, 7(6): 571

［5］Trazler P M, Furet P, Marc L, et al. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of ATP-binding site of the eGFR. J Pharm Belg, 1997, 52(2): 88

［6］Traxler P M, Bold G, Frei J, et al. Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: 4(phenylamino) pyrazolo-[3,4-d] pyrimidines. J Med Chem, 1997, 40(22): 3601

［7］Gordon W, Alexander J B, David W F, et al. PTK inhibitors 12 synthesis and structure-activity relationships for 6-substituted 4-(phenylamino) pyrimido [5,4-d] pyrimidines designed as inhibitor of the eGFR. J Med Chem, 1997, 40(12): 1820

［8］Thompson A M, Alexander J B, David W F, et al. Tyrosine kinase inhibitor 7,7-amino-4(phenylamino)-and 7-amino-4-[(phenylmethyl)amino] pyrido [4,3-d]-primidines; a new class of inhibitor of the tyrosine kinase activity of the eGPR. J Med Chem, 1995, 38(19): 3780-8

［9］Zhu Jiangyum, Shore S K c-ABLtyrosine kinase activity is regulated by association with a novel SH3-domain-binding protein. Mol Cell biol, 1996, 16(12): 7054

［10］Nishi T, Budde R J A, John S, et al. Tight-binding inhibitory sequences against pp60c-Src identified using a random 15-amino acid peptide. FEBS lett, 1996, 399(3): 237

［11］Garcia-Echeverria C. Acylated oligopeptides containing phosphotyrosine as inhibitors of protein tyrosine kinase. PCT Int Appl, 1997, Feb, 27: 07131

［12］Garia-Echeverria C, Gay B. Acylated oligopeptide derivatives having cell signal inhibitory activity. PCT Int Appl 1997, Mar, 6: 08193

［13］Battisjini C, Ballinari T. Substituted indolymethylene-oxindol analogs as tyrosine kinase inhibitors. PCT Iht Appl WO, 96: 32380

［14］Showalter H D H, Sereel A D, Boguslawa M L, et al. Tyrosine kinase inhibitors 6 structure-activity relationship among Nand 3-substituted2,2′-diselenobis (1H-indoles) for inhibition of protein tyrosine kinase and comparative in vitro and in vivo studies against selected sulfur congeners. J Med chem, 1997, 40(4): 413

［15］Burns C J, Howell C. Effect of PTK inhibitors on β-cell proliferation. Biochem Soc trand, 1997, 25(1): 177S

［16］Imoto M, Simizu S, Doki Y, et al. Induction of apoptotic cell death by PTK inhibitor. Nippon Nogei Kayaku kaishi, 1997, 71(5): 523

［17］Iwagoe H, Hivotsugu K, Kazuhiko F, et al. Inhibitory effect of tyrosine kinase inhibitors in antigen-induced tracheal contraction and histamine release in guinea pigs. International Achires of Allergy and Immunology, 1996, 111(3): 291

［18］Masumoto N, Nakayama K. Specific attenuation of the pressure-induced contraction of rat cerebral artery by herbmycin A. Eur J pharmacol, 1997, 330(1): 55

［19］Grignon S, Nicolas L, Francois C, et al. Tyrosine kinase inhibitors and cycloheximide inhibit Li+ protection of cerebella granular neurons switched to nondepolarizing medium. Eur J Pharrfiacol 1996, 315(1): 111

［20］Nakagohri T, Asano T. Effects of tyrosine kinase inhibitor on liver ischemic reperfusion injuries. Ther Res 1996, 17(11) 4206

［21］Ma H, Hiroshi M, Bing L, et al. Regulation of PDGF-βreceptor-operated Ca+ channels by phospholipase c-ri in glomerular mesangial cells. Amer Physiol, 1996, 271 (5 part 2): F994

［22］Wu Jiying, Cohen I S. Tyrosine kinase inhibition reduces if in rabbit ainoatrial node myocytes. Pfiuegers Arch 1997, 434(5): 509

［23］Paillart C, Caclier E, Denis G, et al. Direct block of voltagesensitive sodium channels by gestein. J Pharmacol Exp Ther, 1997, 280(2): 521

［24］Kralisz U, Cierncewahi C S. Different effect of the tyrosine kinase inhibitors on collagen type 1-induced platelet aggregation and adhesion to this protein. Thromb res, 1997, 86(4): 287

［25］Yura Y, Kusaka J, Taujimoto H, et al. Effect of protein tyrosine kinase inhibitors on the replication of herps simplex virus and the phosphorylation of viral proteins. intervirology, 1997, 40(1): 7

［26］Klein B Y, Tepper S H. Opposing effect of tyrosine kinase inhibitors on mineralization of normal and tumor bone ceils. J Cell biochem, 1997, 65(3): 420